Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study
FT is prevalent among patients with HMs receiving care in underserved populations, and the burden is significantly higher among African American and Hispanic populations.
Authors
- Laurie Laufer (ORCID: https://orcid.org/0000-0002-1749-5404)
- Nishi Shah (ORCID: https://orcid.org/0000-0002-8679-511X)
- Ioannis Mantzaris (ORCID: https://orcid.org/0000-0001-8346-5767)
- Lemchukwu Amaeshi (ORCID: https://orcid.org/0000-0002-8900-2242)
- David Levitz (ORCID: https://orcid.org/0009-0009-3239-0078)
- Kira Gritsman (ORCID: https://orcid.org/0000-0002-1367-1167)
- Noah Kornblum (ORCID: https://orcid.org/0000-0001-5985-2011)
- Bruce D. Rapkin (ORCID: https://orcid.org/0000-0002-5901-5659)
- Mendel Goldfinger (ORCID: https://orcid.org/0000-0002-4347-173X)
- Kateryna Fedorov (ORCID: https://orcid.org/0009-0004-8876-8926)
- Aditi Shastri
- Ridhi Gupta
- Alex Sisto
- Rosmi Mathew
- Marina Y. Konopleva
- Dennis Cooper
- Karen Wright
- Amit Verma
- R Alejandro Sica
- Mimi Kim
- Chenxin Zhang
Institutions
- Rutgers, The State University of New Jersey (US)
- Albert Einstein College of Medicine (US)
- Montefiore Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of California, Los Angeles (US)
- Johnson University (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- JMIR Cancer
- Published
- 2026-01-06
- DOI
- https://doi.org/10.2196/68101
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00